[go: up one dir, main page]

MX2019009848A - Proteínas que se unen a her2, nkg2d y cd16. - Google Patents

Proteínas que se unen a her2, nkg2d y cd16.

Info

Publication number
MX2019009848A
MX2019009848A MX2019009848A MX2019009848A MX2019009848A MX 2019009848 A MX2019009848 A MX 2019009848A MX 2019009848 A MX2019009848 A MX 2019009848A MX 2019009848 A MX2019009848 A MX 2019009848A MX 2019009848 A MX2019009848 A MX 2019009848A
Authority
MX
Mexico
Prior art keywords
nkg2d
proteins
bind her2
her2
bind
Prior art date
Application number
MX2019009848A
Other languages
English (en)
Inventor
Prinz Bianka
P Chang Gregory
F Cheung Ann
Haney William
M Lunde Bradley
Original Assignee
Dragonfly Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc
Publication of MX2019009848A publication Critical patent/MX2019009848A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Prostheses (AREA)

Abstract

Se describen proteínas de unión multiespecíficas que se unen a HER2, el receptor NKG2D y CD16, así como composiciones farmacéuticas y métodos terapéuticos útiles para el tratamiento del cáncer.
MX2019009848A 2017-02-20 2018-02-20 Proteínas que se unen a her2, nkg2d y cd16. MX2019009848A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762461146P 2017-02-20 2017-02-20
PCT/US2018/018771 WO2018152518A1 (en) 2017-02-20 2018-02-20 Proteins binding her2, nkg2d and cd16

Publications (1)

Publication Number Publication Date
MX2019009848A true MX2019009848A (es) 2019-12-19

Family

ID=63170743

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009848A MX2019009848A (es) 2017-02-20 2018-02-20 Proteínas que se unen a her2, nkg2d y cd16.

Country Status (16)

Country Link
US (2) US11884732B2 (es)
EP (2) EP4273258A3 (es)
JP (3) JP7685821B2 (es)
KR (2) KR20190120782A (es)
CN (1) CN110944661A (es)
AU (1) AU2018220736B2 (es)
BR (1) BR112019017197A2 (es)
CA (2) CA3235295C (es)
DK (1) DK3582806T5 (es)
ES (1) ES2955074T3 (es)
FI (1) FI3582806T3 (es)
IL (1) IL268755B2 (es)
MX (1) MX2019009848A (es)
SG (1) SG11201907646YA (es)
WO (1) WO2018152518A1 (es)
ZA (1) ZA201905462B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102050463B1 (ko) 2016-08-10 2019-11-29 아주대학교산학협력단 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물
US11834506B2 (en) 2017-02-08 2023-12-05 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind NKG2D, CD16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancer
US11884732B2 (en) 2017-02-20 2024-01-30 Dragonfly Therapeutics, Inc. Proteins binding HER2, NKG2D and CD16
CN120173123A (zh) * 2017-02-27 2025-06-20 蜻蜓疗法股份有限公司 靶向caix、ano1、间皮素、trop2、cea或紧密连接蛋白-18.2的多特异性结合蛋白
DK3749346T3 (da) 2018-02-08 2024-09-09 Dragonfly Therapeutics Inc Antistof variable domænekombinationer rettet mod nkg2d-receptoren
US12384847B2 (en) 2018-02-08 2025-08-12 Dragonfly Therapeutics, Inc. Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen
SG11202007945UA (en) * 2018-02-20 2020-09-29 Dragonfly Therapeutics Inc Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
EA202091977A1 (ru) * 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
BR112021002276A2 (pt) 2018-08-08 2021-05-04 Dragonfly Therapeutics, Inc. proteínas de ligação a nkg2d, cd16 e um antígeno associado ao tumor
PE20211860A1 (es) 2018-08-08 2021-09-21 Dragonfly Therapeutics Inc Proteinas de union multiespecificas que se unen a bcma, nkg2d y cd16 y metodos de uso
EA202091888A1 (ru) * 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
JP7630426B2 (ja) * 2018-10-23 2025-02-17 ドラゴンフライ セラピューティクス， インコーポレイテッド ヘテロ二量体ｆｃ融合タンパク質
CA3152776A1 (en) * 2019-08-30 2021-03-04 Dragonfly Therapeutics, Inc. Pharmaceutical formulations and dosage regimens for multi-specific binding proteins that bind her2, nkg2d, and cd16 for cancer treatment
US12157771B2 (en) 2020-05-06 2024-12-03 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
JP2023526630A (ja) * 2020-05-21 2023-06-22 メルス ナムローゼ フェンノートシャップ Ｉｇ様分子の製造のための方法および手段
MX2022015498A (es) * 2020-06-11 2023-01-24 Tizona Therapeutics Captadores de celulas inmunitarias biespecificas con especificidad de union para hla-g y otro antigeno.
CN116063550A (zh) * 2020-09-02 2023-05-05 南京北恒生物科技有限公司 靶向nk激活性受体的嵌合抗原受体
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
WO2022258691A1 (en) * 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
WO2023056252A1 (en) * 2021-09-29 2023-04-06 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and baff-r
JP2025534206A (ja) 2022-09-15 2025-10-15 アビディキュア アイピー ビー．ブイ． Ｎｋ細胞を刺激するための多重特異性抗原結合タンパク質及びその使用
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
WO2025191137A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Conjugates of trop2-specific antigen binding proteins and cytokines

Family Cites Families (274)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0366707A1 (en) 1987-05-06 1990-05-09 OOSTERWIJK, Egbert Monoclonal antibodies to renal cell carcinoma
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
EP0415929A1 (en) 1988-01-15 1991-03-13 Centocor, Inc. Heteroligating antibodies and therapeutic uses thereof
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6004554A (en) 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6036955A (en) 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US5660827A (en) 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0871673B1 (en) 1995-05-03 2006-04-05 Bioenhancementsments Ltd. Bispecific antibodies in which the binding capability is reversibly inhibited by a photocleavable moiety
DE19531346A1 (de) 1995-08-25 1997-02-27 Gsf Forschungszentrum Umwelt Arzneimittel zur Immuntherapie, enthaltend Antikörper, die spezifisch das MHCII-Antigen eines zu behandelnden Patienten erkennen
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DE69909459T2 (de) 1998-04-21 2004-05-27 Micromet Ag Cd19xcd3 spezifische polypeptide und deren verwendung
US6572856B1 (en) 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
ATE370967T1 (de) 1998-10-21 2007-09-15 Altor Bioscience Corp Polyspezifische bindemoleküle und deren verwendung
CA2406993A1 (en) 2000-03-24 2001-09-27 Micromet Ag Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
EP1299419A2 (en) 2000-05-24 2003-04-09 Imclone Systems, Inc. Bispecific immunoglobulin-like antigen binding proteins and method of production
US20040115198A1 (en) 2001-02-28 2004-06-17 Fred Hutchinson Cancer Research Center Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives
US20020193569A1 (en) 2001-06-04 2002-12-19 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
DE10156482A1 (de) 2001-11-12 2003-05-28 Gundram Jung Bispezifisches Antikörper-Molekül
UA87979C2 (ru) 2002-08-19 2009-09-10 Астразенека Аб Человеческое моноклональное антитело, которое нейтрализует моноцитарный хемоатрактантный белок (мср-1)
US7820166B2 (en) 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
DE10261223A1 (de) 2002-12-20 2004-07-08 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen
WO2004069876A2 (en) 2003-02-06 2004-08-19 Micromet Ag Trimeric polypeptide construct to induce an enduring t cell response
US7666417B2 (en) 2003-04-22 2010-02-23 Fred Hutchinson Cancer Research Center Methods and compositions for treating autoimmune diseases or conditions
WO2004106381A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
AU2004242845B2 (en) 2003-05-31 2011-06-02 Amgen Research (Munich) Gmbh Human-anti-human CD3 binding molecules
PT1648507T (pt) 2003-07-24 2017-03-20 Innate Pharma Sa Métodos e composições para aumentar a eficácia de anticorpos terapêuticos utilizando compostos potenciadores de células nk
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US8076459B2 (en) 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
US20110020273A1 (en) 2005-04-06 2011-01-27 Ibc Pharmaceuticals, Inc. Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
MXPA06009253A (es) 2004-02-16 2007-04-18 Micromet Ag Moleculas de enlace menos inmunogenicas.
JP5014988B2 (ja) 2004-07-16 2012-08-29 マイクロメット アクツィエン ゲゼルシャフト 発現増強ポリペプチド
KR20150043558A (ko) * 2004-07-22 2015-04-22 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
JP2008514685A (ja) 2004-10-01 2008-05-08 メディジーン リミテッド 治療剤に連結した、非天然型ジスルフィド鎖間結合を含有するｔ細胞レセプター
DOP2006000029A (es) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
ES2971647T3 (es) 2005-04-15 2024-06-06 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
EP1909832A4 (en) 2005-06-29 2010-01-13 Univ Miami ANTIBODY IMMUNOCELL LIGAND FUSION PROTEIN FOR CANCER THERAPY
EP1928495A2 (en) 2005-08-19 2008-06-11 Cerus Corporation Antibody-mediated enhancement of immune response
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
EP1940881B1 (en) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
CA2623109C (en) 2005-10-14 2019-02-19 Innate Pharma Nk cell-depleting antibodies for treating immunoproliferative disorders
JP2009513608A (ja) 2005-10-28 2009-04-02 ノボ・ノルデイスク・エー／エス エフェクターリンパ球と標的細胞とを結合する融合タンパク質
JP2009514528A (ja) 2005-11-03 2009-04-09 フレッド ハッチンソン キャンサー リサーチ センター Ｎｋｇ２ｄ陽性ｃｄ４＋細胞による免疫応答の負の免疫調節法
WO2007097812A2 (en) 2005-11-03 2007-08-30 Genentech, Inc. Therapeutic anti-her2 antibody fusion polypeptides
AU2006326727A1 (en) 2005-12-16 2007-06-21 Amgen Research (Munich) Gmbh Means and methods for the treatment of tumorous diseases
EP1820513A1 (en) 2006-02-15 2007-08-22 Trion Pharma Gmbh Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
US8409577B2 (en) 2006-06-12 2013-04-02 Emergent Product Development Seattle, Llc Single chain multivalent binding proteins with effector function
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
JP5161882B2 (ja) 2006-09-07 2013-03-13 クルセル ホランド ベー ヴェー インフルエンザウイルスｈ５ｎ１を中和しうるヒト結合性分子およびその使用
EP1900752A1 (en) 2006-09-15 2008-03-19 DOMPE' pha.r.ma s.p.a. Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
US20090252729A1 (en) 2007-05-14 2009-10-08 Farrington Graham K Single-chain Fc (scFc) regions, binding polypeptides comprising same, and methods related thereto
EP2014680A1 (en) 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
AU2008278803A1 (en) 2007-07-25 2009-01-29 Astrazeneca Ab Targeted binging agents directed to KDR and uses thereof - 035
CA2695374A1 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
WO2009036379A2 (en) 2007-09-14 2009-03-19 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
TWI468174B (zh) * 2007-12-14 2015-01-11 Novo Nordisk As 針對人類ｎｋｇ２ｄ的抗體及其用途
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
AU2009206724A1 (en) 2008-01-22 2009-07-30 Biogen Idec Ma Inc. RON antibodies and uses thereof
NZ589436A (en) * 2008-06-03 2012-12-21 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US8067339B2 (en) 2008-07-09 2011-11-29 Merck Sharp & Dohme Corp. Surface display of whole antibodies in eukaryotes
US9273136B2 (en) * 2008-08-04 2016-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human anti-human NKG2D monoclonal antibodies
EP2352758A2 (en) 2008-09-26 2011-08-10 Wyeth LLC Single chain antibody library design
EP2356270B1 (en) 2008-11-07 2016-08-24 Fabrus Llc Combinatorial antibody libraries and uses thereof
ES2550384T3 (es) 2008-12-18 2015-11-06 Dana-Farber Cancer Institute, Inc. NKG2D-Fc para la inmunoterapia
MX2011006416A (es) 2008-12-19 2011-07-12 Macrogenics Inc Diacuerpos covalentes y sus usos.
JP5587975B2 (ja) 2009-04-07 2014-09-10 ロシュ グリクアート アクチェンゲゼルシャフト 二重特異的抗−ＥｒｂＢ−３／抗−ｃ−Ｍｅｔ抗体
US20120058082A1 (en) 2009-05-13 2012-03-08 Genzyme Corporation Methods and compositions for treatment
WO2010144295A1 (en) 2009-06-09 2010-12-16 University Of Miami Aptamer-targeted costimulatory ligand aptamer
US9050375B2 (en) 2009-07-06 2015-06-09 Hoffmann-La Roche, Inc. Bi-specific digoxigenin binding antibodies
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011030851A1 (ja) 2009-09-11 2011-03-17 タカラバイオ株式会社 ナチュラルキラー細胞の製造方法
HUE025759T2 (en) 2009-10-27 2016-04-28 Amgen Res Munich Gmbh Dosage regimen for administering a cd19xcd3 bispecific antibody
WO2011057124A1 (en) 2009-11-06 2011-05-12 Transtarget, Inc. Polyclonal bispecific antibody compositions and method of use
EP2332994A1 (en) 2009-12-09 2011-06-15 Friedrich-Alexander-Universität Erlangen-Nürnberg Trispecific therapeutics against acute myeloid leukaemia
US20120288507A1 (en) 2009-12-18 2012-11-15 Amgen Inc. Wise binding agents and epitopes
US8796420B2 (en) 2009-12-31 2014-08-05 Avidbiotics Corp. Non-natural MIC proteins
US8658765B2 (en) 2009-12-31 2014-02-25 Avidbiotics Corp. Non-natural MIC proteins
WO2011085178A1 (en) 2010-01-11 2011-07-14 Trustees Of Dartmouth College Monomeric bi-specific fusion protein
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
LT2542256T (lt) 2010-03-04 2019-10-25 Macrogenics Inc Su b7-h3 reaguojantys antikūnai, jų imunologiškai aktyvūs fragmentai ir jų naudojimas
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
CN110066339A (zh) 2010-04-20 2019-07-30 根马布股份公司 含异二聚体抗体fc的蛋白及其制备方法
JP6022444B2 (ja) 2010-05-14 2016-11-09 ライナット ニューロサイエンス コーポレイション ヘテロ二量体タンパク質ならびにそれを生産および精製するための方法
CN103347894B (zh) 2010-06-19 2017-05-10 纪念斯隆-凯特林癌症中心 抗gd2抗体
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
DE102010039018B4 (de) 2010-08-06 2013-02-28 Technische Universität Dresden Anti-La Antikörper und ihre Anwendung zum Immunotargeting
EP2603526A1 (en) 2010-08-13 2013-06-19 Medimmune Limited Monomeric polypeptides comprising variant fc regions and methods of use
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
UY33578A (es) 2010-08-31 2012-03-30 Sanofi Sa PÉPTIDO O COMPLEJO PEPTÍDICO QUE SE UNE A INTEGRINA a(ALFA) Y MÉTODOS Y USOS QUE IMPLICAN A LOS MISMOS
WO2012032080A1 (en) 2010-09-07 2012-03-15 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Stabilised human fc
AU2011299066A1 (en) 2010-09-10 2013-03-21 Apexigen, Inc. Anti-IL-1 beta antibodies and methods of use
WO2012061558A2 (en) 2010-11-04 2012-05-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
HUE047228T2 (hu) 2010-11-05 2020-04-28 Zymeworks Inc Stabil heterodimer antitest-kialakítás az FC doménben mutációval
US9518132B2 (en) 2010-11-09 2016-12-13 Altimab Therapeutics, Inc. Protein complexes for antigen binding and methods of use
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
CA2827923C (en) 2011-02-25 2021-11-23 Chugai Seiyaku Kabushiki Kaisha Fc.gamma.riib-specific fc antibody
US20140112926A1 (en) 2011-03-16 2014-04-24 Amgen Inc. Fc VARIANTS
KR20200052383A (ko) 2011-03-25 2020-05-14 아이크노스 사이언스 에스. 아. 헤테로 이량체 면역글로불린
WO2015070061A1 (en) 2013-11-07 2015-05-14 Memorial Sloan-Kettering Cancer Center Anti-wt1/hla bi-specific antibody
CN103842383B (zh) 2011-05-16 2017-11-03 健能隆医药技术（上海）有限公司 多特异性fab融合蛋白及其使用方法
MX347818B (es) 2011-05-21 2017-05-15 Macrogenics Inc Dominios que enlazan suero desinmunizados y su uso para prolongar la vida media en suero.
CA2837169C (en) * 2011-05-24 2021-11-09 Zyngenia, Inc. Multispecific complexes comprising angiopoietin-2-binding peptide and their uses
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
EP2723362A1 (en) 2011-06-21 2014-04-30 Innate Pharma NKp46-MEDIATED NK CELL TUNING
DE102011118022B4 (de) 2011-06-30 2018-01-18 Gemoab Monoclonals Gmbh Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung
MX340498B (es) 2011-06-30 2016-07-11 Chugai Pharmaceutical Co Ltd Polipeptido heterodimerizado.
JP5938473B2 (ja) 2011-07-22 2016-06-22 アフィメート テラポイティクス アーゲー 多価抗原結合Ｆｖ分子
US10040853B2 (en) 2011-09-09 2018-08-07 Fred Hutchinson Cancer Research Center Methods and compositions involving NKG2D inhibitors and cancer
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
EP2762564B1 (en) 2011-09-30 2020-09-16 Chugai Seiyaku Kabushiki Kaisha Ion concentration-dependent binding molecule library
EA201400709A1 (ru) 2011-12-19 2016-08-31 Синиммун Гмбх Молекула биспецифического антитела
KR102102111B1 (ko) 2012-02-08 2020-04-20 아이쥐엠 바이오사이언스 인코포레이티드 Ｃｄｉｍ 결합 단백질 및 이의 용도
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US9029510B2 (en) 2012-03-30 2015-05-12 Sorrento Therapeutics, Inc. Fully human antibodies that bind to VEGFR2 and methods of use thereof
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
US9163090B2 (en) 2012-05-07 2015-10-20 Cellerant Therapeutics, Inc. Antibodies specific for CLL-1
CN104487457B (zh) 2012-05-30 2018-01-26 中外制药株式会社 靶组织特异性抗原结合分子
JP6628966B2 (ja) 2012-06-14 2020-01-15 中外製薬株式会社 改変されたＦｃ領域を含む抗原結合分子
CA2877573A1 (en) 2012-06-21 2013-12-27 Sorrento Therapeutics, Inc. Antigen binding proteins that bind c-met
RU2639287C2 (ru) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
AU2013289883B2 (en) 2012-07-13 2018-11-01 Zymeworks Bc Inc. Bispecific asymmetric heterodimers comprising anti-CD3 constructs
CN104640561A (zh) 2012-07-23 2015-05-20 酵活有限公司 包含轻链和重链的选择性配对的免疫球蛋白构建体
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
EP2885002A4 (en) 2012-08-14 2016-04-20 Ibc Pharmaceuticals Inc BISPECIFIC ANTIBODIES REDIRECTED AGAINST T CELLS FOR THE TREATMENT OF DISEASES
PT2900694T (pt) * 2012-09-27 2018-11-13 Merus Nv Anticorpos de igg biespecíficos como ativadores de células t
CN120365432A (zh) 2012-11-21 2025-07-25 武汉友芝友生物制药股份有限公司 双特异性抗体
KR101522954B1 (ko) 2012-11-27 2015-05-27 아주대학교산학협력단 항체 중쇄불변부위의 이종이중체 고효율 형성을 유도하는 ch3 도메인 변이체 쌍, 이의 제조방법, 및 용도
KR20160007478A (ko) * 2013-01-10 2016-01-20 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10738132B2 (en) 2013-01-14 2020-08-11 Xencor, Inc. Heterodimeric proteins
US20140242077A1 (en) 2013-01-23 2014-08-28 Abbvie, Inc. Methods and compositions for modulating an immune response
EP2953974B1 (en) 2013-02-05 2017-12-20 EngMab Sàrl Bispecific antibodies against cd3epsilon and bcma
NZ708182A (en) 2013-02-26 2019-08-30 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
SI2968520T1 (sl) 2013-03-14 2022-01-31 Macrogenics, Inc. Bispecifične molekule, ki so imunoreaktivne z imunskimi efektorskimi celicami, ki izražajo aktivacijski receptor
AU2014228772B2 (en) 2013-03-15 2019-02-28 Memorial Sloan Kettering Cancer Center High affinity anti-GD2 antibodies
US10858417B2 (en) * 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
EP3587448B1 (en) * 2013-03-15 2021-05-19 Xencor, Inc. Heterodimeric proteins
WO2014165818A2 (en) 2013-04-05 2014-10-09 T Cell Therapeutics, Inc. Compositions and methods for preventing and treating prostate cancer
WO2014179363A1 (en) 2013-04-29 2014-11-06 Adimab, Llc Polyspecificity reagents, methods for their preparation and use
EP3415534A1 (en) 2013-05-10 2018-12-19 Numab Therapeutics AG Bispecific constructs and their use in the treatment of various diseases
EP3008093A1 (en) * 2013-06-11 2016-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-her2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer
EP3022229A1 (en) 2013-07-15 2016-05-25 Novo Nordisk A/S Antibodies that bind urokinase plasminogen activator
SI3021869T1 (sl) 2013-07-16 2020-10-30 F. Hoffmann-La Roche Ag Postopki zdravljenja raka z uporabo antagonistov in inhibitorjev TIGIT, ki se vežejo na os PD-1
HRP20220553T1 (hr) 2013-07-25 2022-06-10 Cytomx Therapeutics Inc. Polispecifična protutijela, polispecifična protutijela koja se mogu aktivirati i postupci uporabe navedenih protutijela
GB2518221A (en) 2013-09-16 2015-03-18 Sergej Michailovic Kiprijanov Tetravalent antigen-binding protein molecule
WO2015036606A1 (en) 2013-09-16 2015-03-19 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Bi- or multispecific polypeptides binding immune effector cell surface antigens and hbv antigens for treating hbv infections and associated conditions
GB2519786A (en) 2013-10-30 2015-05-06 Sergej Michailovic Kiprijanov Multivalent antigen-binding protein molecules
DE102013019352A1 (de) 2013-11-13 2015-09-17 Elke Pogge Von Strandmann Tri-spezifische rekombinante Antikörperderivate zur Behandlung von malignen Erkrankungen durch Aktivierung einer NK-Zell-basierten Immunantwort
PT3074424T (pt) 2013-11-27 2025-05-29 Zymeworks Bc Inc Construções de ligação a antigénio biespecíficas direcionadas a her2
PE20160712A1 (es) 2013-12-13 2016-07-26 Genentech Inc Anticuerpos e inmunoconjugados anti-cd33
WO2015095412A1 (en) 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
JP7325166B2 (ja) 2013-12-20 2023-08-14 ジェネンテック， インコーポレイテッド 二重特異性抗体
KR20160099087A (ko) 2013-12-20 2016-08-19 에프. 호프만-라 로슈 아게 이중특이성 her2 항체 및 사용 방법
EP3087185A4 (en) 2013-12-23 2017-09-06 Zymeworks Inc. Antibodies comprising c-terminal light chain polypeptide extensions and conjugates and methods of use thereof
AU2014374055B2 (en) 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
AU2015206407A1 (en) 2014-01-15 2016-08-18 Zymeworks Inc. Bi-specific CD3 and CD19 antigen-binding constructs
ES2758173T3 (es) 2014-03-05 2020-05-04 Ucl Business Ltd Receptor quimérico de antígeno (CAR) con dominios de unión a antígeno para la región constante de receptores de linfocitos T beta
WO2015153514A1 (en) 2014-03-31 2015-10-08 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
EP3126384B1 (en) 2014-04-01 2020-12-02 Adimab, LLC Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
PT3126383T (pt) 2014-04-03 2019-03-22 Igm Biosciences Inc Cadeia j modificada
HK1232127A1 (zh) 2014-04-11 2018-01-05 Medimmune, Llc 双特异性her2抗体
EP2930188A1 (en) 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
EP2942629A1 (en) 2014-05-08 2015-11-11 Universität Würzburg Predictive markers for successful cancer immunotherapy
EP3152235B1 (en) 2014-05-29 2021-08-25 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
CA2952727A1 (en) 2014-06-27 2015-12-30 Innate Pharma Multispecific nkp46 binding proteins
WO2015197582A1 (en) 2014-06-27 2015-12-30 Innate Pharma Monomeric multispecific antigen binding proteins
US11208480B2 (en) 2014-06-27 2021-12-28 Innate Pharma Multispecific antigen binding proteins
US9777073B2 (en) 2014-07-21 2017-10-03 Wuhan Yzy Biopharma Co., Ltd. Construction and application of bispecific antibody EpCAM×CD3
WO2016011571A1 (en) 2014-07-21 2016-01-28 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody-mediated cancer therapy with cytokine-induced killer cell
US9777061B2 (en) 2014-07-21 2017-10-03 Novartis Ag Treatment of cancer using a CD33 chimeric antigen receptor
AU2015301460B2 (en) 2014-08-14 2021-04-08 Novartis Ag Treatment of cancer using GFR alpha-4 chimeric antigen receptor
EP2985294A1 (en) 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Recombinant antibody molecule and its use for target cell restricted T cell activation
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
EP3186282A1 (en) 2014-08-28 2017-07-05 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations
ES2688035T3 (es) 2014-08-29 2018-10-30 Gemoab Monoclonals Gmbh Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
CN107074961A (zh) 2014-11-03 2017-08-18 默克专利股份公司 用于生成双特异性鲨鱼可变抗体结构域的方法及其用途
CN107001482B (zh) 2014-12-03 2021-06-15 豪夫迈·罗氏有限公司 多特异性抗体
CA2963274C (en) 2014-12-05 2024-01-30 Avidbiotics Corp. Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands
CA2970255A1 (en) 2014-12-17 2016-06-23 Intrexon Corporation Intercalated single-chain variable fragments
US10941207B2 (en) 2014-12-19 2021-03-09 Chiome Bioscience, Inc Fusion protein comprising three binding domains to 5T4 and CD3
EP4670785A2 (en) 2015-01-02 2025-12-31 Takeda Pharmaceutical Company Limited Bispecific antibodies against plasma kallikrein and factor XII
BR112017015136A2 (pt) 2015-01-14 2018-01-30 Compass Therapeutics Llc polipeptídeo de construto de ligação ao antígeno imunomodulador multiespecífico, construto de ligação ao antígeno imunomodulador multiespecífico, conjugado, composição farmacêutica, método para tratar um indivíduo com câncer, método para inibir ou reduzir o crescimento de câncer, composição, célula, método de fazer um polipeptídeo de construto de ligação ao antígeno imunomodulador multiespecífico, vetor ou conjunto de vetores e kit
WO2016122701A1 (en) 2015-01-26 2016-08-04 Macrogenics, Inc. Anti-dr5 antibodies and molecules comprising dr5-binding domains thereof
CN107530424A (zh) 2015-02-20 2018-01-02 俄亥俄州国家创新基金会 针对nkg2d和肿瘤相关抗原的二价抗体
MA41613A (fr) 2015-02-23 2018-01-02 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
US11673957B2 (en) 2015-03-10 2023-06-13 Eureka Therapeutics, Inc. Anti-ROR2 antibodies
RU2733496C2 (ru) 2015-03-16 2020-10-02 Гельмгольц Центрум Мюнхен - Дойчес Форшунгсцентрум Фюр Гезундхайт Унд Умвельт (Гмбх) Триспецифические связывающие молекулы для лечения вирусной инфекции гепатита в и связанных состояний
HK1249048A1 (zh) 2015-04-03 2018-10-26 Eureka Therapeutics, Inc. 靶向afp肽/mhc复合体的构建体及其用途
KR102788389B1 (ko) 2015-04-06 2025-03-31 서브도메인, 엘엘씨 드 노보 결합 도메인 함유 폴리펩티드 및 그의 용도
LT3280441T (lt) 2015-04-07 2021-11-25 Alector Llc Anti-sortilino antikūnai ir jų naudojimo būdai
WO2016166139A1 (en) 2015-04-14 2016-10-20 Eberhard Karls Universität Tübingen Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
EP3842072A1 (en) 2015-05-18 2021-06-30 Eureka Therapeutics, Inc. Anti-ror1 antibodies
EP3095792A1 (en) 2015-05-19 2016-11-23 Klinikum rechts der Isar der Technischen Universität München T cell receptor with specificity for myeloperoxidase peptide and uses thereof
US20180147257A1 (en) 2015-05-22 2018-05-31 The Board Of Trustees Of The Leland Stanford Junior University Btn3a ectodomain proteins and methods of use
PT3303396T (pt) 2015-05-29 2023-01-30 Bristol Myers Squibb Co Anticorpos contra ox40 e utilizações dos mesmos
CN107849144B (zh) 2015-05-29 2021-09-17 艾吉纳斯公司 抗-ctla-4抗体及其使用方法
WO2016201389A2 (en) 2015-06-12 2016-12-15 Alector Llc Anti-cd33 antibodies and methods of use thereof
US20160361360A1 (en) 2015-06-12 2016-12-15 Immunomedics, Inc. Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
WO2016207273A2 (en) 2015-06-23 2016-12-29 Innate Pharma Multispecific antigen binding proteins
AU2016284871B2 (en) 2015-06-23 2022-09-29 Innate Pharma Multispecific NK engager proteins
KR102742965B1 (ko) 2015-07-06 2024-12-13 유씨비 바이오파마 에스알엘 타우 결합 항체
WO2017011342A1 (en) 2015-07-10 2017-01-19 Abbvie Inc. Igm-or-ige-modified binding proteins and uses thereof
JP2018524373A (ja) 2015-07-15 2018-08-30 ザイムワークス，インコーポレイテッド 薬物がコンジュゲートされた二重特異性抗原結合コンストラクト
CN108025092A (zh) 2015-07-16 2018-05-11 塞勒兰特治疗公司 经半胱氨酸取代的免疫球蛋白
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
US20180251548A1 (en) 2015-09-14 2018-09-06 Compass Therapeutics Llc Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-beta
CN115594765A (zh) 2015-10-02 2023-01-13 豪夫迈·罗氏有限公司（Ch） 对共刺激性tnf受体特异性的双特异性抗体
US10800844B2 (en) 2015-10-29 2020-10-13 Alector Llc Anti-Siglec-9 antibodies and methods of use thereof
CN108779174B (zh) 2015-11-04 2022-11-29 希望之城公司 靶向her2的嵌合抗原受体
EP3373952A4 (en) 2015-11-10 2019-05-22 Fred Hutchinson Cancer Research Center NKG2D decoys
WO2017081190A1 (en) 2015-11-13 2017-05-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti- nkg2d single domain antibodies and uses thereof
CN108779175B (zh) 2015-12-28 2022-07-08 依奈特制药公司 NKp46结合蛋白的可变区
CA3011535A1 (en) 2016-01-13 2017-07-20 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
WO2017125897A1 (en) 2016-01-21 2017-07-27 Novartis Ag Multispecific molecules targeting cll-1
UY37127A (es) 2016-02-17 2017-08-31 Macrogenics Inc Moléculas de unión a ror1, y métodos de uso de las mismas
CN109310766A (zh) 2016-02-26 2019-02-05 伊蒙纽斯私人有限公司 多特异性分子
WO2017165464A1 (en) 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
AU2017251116A1 (en) 2016-04-15 2018-12-06 Zymeworks Inc. Multi-specific antigen-binding constructs targeting immunotherapeutics
GEAP202214922A (en) 2016-04-15 2022-02-10 Macrogenics Inc Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof
GB201610044D0 (en) 2016-06-08 2016-07-20 Ucb Biopharma Sprl Antibodies
MX2018015592A (es) 2016-06-14 2019-04-24 Xencor Inc Anticuerpos inhibidores de puntos de control biespecificos.
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
CN105906722B (zh) 2016-06-24 2020-02-07 安徽未名细胞治疗有限公司 一种Her2特异性嵌合抗原受体及其应用
AU2017319519A1 (en) 2016-09-01 2019-04-18 Immunomab, Inc. Bispecific antibodies
WO2018071777A1 (en) 2016-10-14 2018-04-19 Harpoon Therapeutics, Inc. Innate immune cell trispecific binding proteins and methods of use
JP2019535250A (ja) 2016-10-29 2019-12-12 ジェネンテック， インコーポレイテッド 抗ｍｉｃ抗体及び使用方法
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
JOP20190134A1 (ar) 2016-12-23 2019-06-02 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
WO2018148447A1 (en) 2017-02-08 2018-08-16 Adimab, Llc Antibody heavy chain variable domains targeting the nkg2d receptor
US11834506B2 (en) * 2017-02-08 2023-12-05 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind NKG2D, CD16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancer
US20200024353A1 (en) 2017-02-10 2020-01-23 Dragonfly Therapeutics, Inc. Proteins binding psma, nkg2d and cd16
JP7257323B2 (ja) 2017-02-10 2023-04-13 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｂｃｍａ、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質
EP3583132A4 (en) 2017-02-20 2020-11-04 Dragonfly Therapeutics, Inc. PROTEINS THAT BIND CD123, NKG2D AND CD16
MA47508A (fr) 2017-02-20 2021-03-17 Dragonfly Therapeutics Inc Protéines de liaison à cd33, nkg2d et cd16
CN110891976A (zh) 2017-02-20 2020-03-17 蜻蜓疗法股份有限公司 结合gd2、nkg2d和cd16的蛋白质
US11884732B2 (en) 2017-02-20 2024-01-30 Dragonfly Therapeutics, Inc. Proteins binding HER2, NKG2D and CD16
CN120173123A (zh) 2017-02-27 2025-06-20 蜻蜓疗法股份有限公司 靶向caix、ano1、间皮素、trop2、cea或紧密连接蛋白-18.2的多特异性结合蛋白
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
US20200157227A1 (en) 2017-05-23 2020-05-21 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and a tumor-associated antigen
BR112019024654A2 (pt) 2017-05-23 2020-06-09 Dragonfly Therapeutics Inc proteína de ligação nkg2d, cd16 e ror1 ou ror2
CN111278460A (zh) 2017-05-23 2020-06-12 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
CA3070986A1 (en) 2017-07-31 2019-02-07 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and flt3
SG10202102251YA (en) 2017-08-16 2021-04-29 Dragonfly Therapeutics Inc Proteins binding nkg2d, cd16, and egfr, hla-e ccr4, or pd-l1
JP2020531525A (ja) 2017-08-23 2020-11-05 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍−関連抗原に結合するタンパク質
US20200277383A1 (en) 2017-09-07 2020-09-03 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and a tumor-associated antigen
CA3075857A1 (en) 2017-09-14 2019-03-21 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16, and c-type lectin-like molecule-1 (cll-1)
DK3749346T3 (da) 2018-02-08 2024-09-09 Dragonfly Therapeutics Inc Antistof variable domænekombinationer rettet mod nkg2d-receptoren
US12384847B2 (en) 2018-02-08 2025-08-12 Dragonfly Therapeutics, Inc. Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen
US20200376034A1 (en) 2018-02-20 2020-12-03 Dragonfly Therapeutics, Inc. Antibody variable domains targeting cd33, and use thereof
SG11202007945UA (en) 2018-02-20 2020-09-29 Dragonfly Therapeutics Inc Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
US20210221894A1 (en) 2018-04-03 2021-07-22 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams
CN112437672A (zh) 2018-05-07 2021-03-02 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
BR112020023299A2 (pt) 2018-05-16 2021-02-02 Dragonfly Therapeutics, Inc. proteína de ligação nkg2d, cd16 e uma proteína de ativação de fibroblastos
EA202091977A1 (ru) 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
MX2021001510A (es) 2018-08-08 2021-07-02 Dragonfly Therapeutics Inc Proteínas de union a nkg2d, cd16, y un antígeno asociado a tumores.
CR20210687A (es) 2019-06-25 2022-03-03 Gilead Sciences Inc PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO
AR119393A1 (es) 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
CA3152776A1 (en) 2019-08-30 2021-03-04 Dragonfly Therapeutics, Inc. Pharmaceutical formulations and dosage regimens for multi-specific binding proteins that bind her2, nkg2d, and cd16 for cancer treatment
US12157771B2 (en) 2020-05-06 2024-12-03 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A

Also Published As

Publication number Publication date
ZA201905462B (en) 2024-07-31
DK3582806T5 (da) 2024-09-02
JP2022101687A (ja) 2022-07-06
SG11201907646YA (en) 2019-09-27
EP4273258A3 (en) 2024-01-17
EP3582806A4 (en) 2020-12-16
IL268755A (en) 2019-10-31
US20240228625A1 (en) 2024-07-11
EP4273258A2 (en) 2023-11-08
AU2018220736A1 (en) 2019-09-05
WO2018152518A1 (en) 2018-08-23
IL268755B2 (en) 2025-12-01
DK3582806T3 (da) 2023-09-11
JP2024024048A (ja) 2024-02-21
IL268755B1 (en) 2025-08-01
ES2955074T3 (es) 2023-11-28
CA3054079A1 (en) 2018-08-23
AU2018220736B2 (en) 2024-10-24
CA3235295C (en) 2024-11-19
KR20190120782A (ko) 2019-10-24
CA3235295A1 (en) 2018-08-23
US11884732B2 (en) 2024-01-30
EP3582806A1 (en) 2019-12-25
EP3582806B1 (en) 2023-07-26
JP2020508997A (ja) 2020-03-26
JP7685821B2 (ja) 2025-05-30
KR20240060739A (ko) 2024-05-08
CN110944661A (zh) 2020-03-31
US20200231678A1 (en) 2020-07-23
BR112019017197A2 (pt) 2020-04-14
FI3582806T3 (fi) 2023-09-07

Similar Documents

Publication Publication Date Title
MX2019009848A (es) Proteínas que se unen a her2, nkg2d y cd16.
MX2020002626A (es) Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumores.
CO2020001981A2 (es) Proteínas que se unen a nkg2d, cd16 y flt3
CO2022004757A2 (es) Proteínas que se unen a nkg2d, cd16 y flt3
MX2019009468A (es) Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer.
CL2022003077A1 (es) Proteínas que se unen a nkg2d, cd16 y clec12a
MX2019010156A (es) Proteínas multiespecíficas de unión de direccionamiento a anhidrasa carbónica 9 (caix), anoctamina-1 (ano1), mesotelina, antígeno de superficie celular de trofoblasto (trop2), antígeno carcinoembrionario (cea) o claudina-18.2.
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CL2023002108A1 (es) Proteínas unión multiespecíficas se unen a cd33, nkg2d, cd16, métodos de uso.
MY205850A (en) Proteins binding bcma, nkg2d and cd16
MX2020012273A (es) Proteína de union a nkg2d, cd16 y proteína de activación de fibroblastos.
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
MX2018015853A (es) Anticuerpos multiespecificos frente a los grupos de diferenciacion 40 y 137 (cd40 y cd137).
MX2020006668A (es) Anticuerpos para lilrb2.
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
MX2017014822A (es) Composiciones y métodos para la reprogramación del tcr con proteínas de fusión.
MX2017001031A (es) Móleculas de unión a her2 y cd3 biespecíficas.
MX2016017311A (es) Composiciones de portador-anticuerpo y metodos para realizarlas y utilizarlas.
MX2017014375A (es) Moduladores del ccr2.
BR112023002116A2 (pt) Proteínas que se ligam a nkg2d, cd16 e egfr
CO2017003005A2 (es) Anticuerpos anti-mfi2
MX2019009847A (es) Proteínas que se unen a cd123, nkg2d y cd16.
CL2024000922A1 (es) Proteínas que se unen a nkg2d, cd16 y baff-r
MX2019009541A (es) Proteinas que se unen a psma, nkg2d y cd16.